

---

--DETAILED DESCRIPTION OF THE INVENTION

AB The present invention provides improved compositions as well as methods of treatment. More specifically, the composition of the present invention and treatment can be used for the treatment or prevention of sepsis or inflammatory shock. The composition of the present invention includes greater than 35% of its caloric content as a lipid.

By way of example and not limitation, examples of the present invention will now be set forth.--

---

In the Claims:

Please amend Claims 1-8 as follows:

1. A method of treating sepsis comprising the steps of administering to a patient with sepsis a therapeutically effective amount of a composition which comprises at least one lipid wherein the lipid provides greater than 35% of the total energy of the composition.

AY 2. A method of reducing the risk of sepsis comprising the steps of administering to a patient at risk of sepsis comprises a therapeutically effective amount of a composition, which comprises at least one lipid wherein the lipid provides greater than 35% of the total energy of the composition.

3. A method of producing a composition which comprises at least one lipid wherein the lipid provides greater than 35% of the total energy of the composition, comprising the steps of blending constituents including at least one lipid, liquefying a blended mixture and homogenising the liquefied blended mixture to produce a product wherein greater than 35% of the total energy of the composition is provided by lipid.

4. A composition comprising at least one lipid wherein the lipid provides greater than 35% of the total energy of the composition, about 25% to about 70% MCT (medium chain triglycerides) by weight of total lipid and less than about 15% by weight saturated fatty acids excluding MCT.

5. A composition according to claim 4, which comprises a n-6/n-3 fatty acid ratio of about 2/1 to about 7/1.

6. A composition according to claim 4, which comprises at least one n-3 fatty acid selected from the group consisting of  $\alpha$ -linolenic acid, EPA, DPA and DHA.

AM 7. A composition according to claim 4, which comprises at least one n-6 fatty acid selected from the group consisting of linoleic acid (18:2, n-6),  $\gamma$ -linolenic acid (18:3, n-6), dihomo- $\gamma$ -linolenic acid (18:4, n-6) and arachidonic acid (20:4, n-6).

8. A composition according to claim 4 for enteral administration which includes at least one component selected from the group consisting of an acceptable carrier, diluent and adjuvant.

Please add newly-submitted Claims 9-40 as follows:

9. The method of claim 1 wherein the composition is in a form selected from the group consisting of medicament, functional food and nutritive product.

10. A method of treating inflammatory shock comprising the step of administering to a patient suffering inflammatory shock a therapeutically effective amount of a composition which comprises at least one lipid wherein the lipid provides greater than 35% of the total energy of the composition.

AS 11. The method of claim 1 wherein the composition comprises about 25% to about 70% MCT (medium chain triglycerides) by weight of total lipid and less than about 15% by weight saturated fatty acids excluding MCT.

12. The method of claim 1 wherein the composition comprises a n-6/n-3 fatty acid ratio of about 2/1 to about 7/1.

13. The method of claim 1 wherein the composition comprises at least one n-3 fatty acid selected from the group consisting of  $\alpha$ -linolenic acid, EPA, DPA and DHA.

14. The method of claim 1 wherein the composition comprises at least one n-6 fatty acid selected from the group consisting of linoleic acid (18:2, n-6),  $\gamma$ -linolenic acid (18:3, n-6), dihomo- $\gamma$ -linolenic acid (18:4, n-6) and arachidonic acid (20:4, n-6).

15. The method of claim 1 wherein the composition is administered enterally.
16. A method for reducing the risk of inflammatory shock comprising the step of administering to a patient at risk of inflammatory shock a therapeutically effective amount of a composition which comprises at least one lipid wherein the lipid provides greater than 35% of the total energy of the composition.
17. The method of claim 2 wherein the composition is in a form selected from the group consisting of medicament, functional food and nutritive product.
18. The method of claim 2 wherein the composition comprises about 25% to about 70% MCT (medium chain triglycerides) by weight of total lipid and less than about 15% by weight saturated fatty acids excluding MCT.
19. The method of claim 2 wherein the composition comprises a n-6/n-3 fatty acid ratio of about 2/1 to about 7/1.
20. The method of claim 2 wherein the composition comprises at least one n-3 fatty acid selected from the group consisting of  $\alpha$ -linolenic acid, EPA, DPA and DHA.
21. The method of claim 2 wherein the composition comprises at least one n-6 fatty acid selected from the group consisting of linoleic acid (18:2, n-6),  $\gamma$ -linolenic acid (18:3, n-6), dihomo- $\gamma$ -linolenic acid (18:4, n-6) and arachidonic acid (20:4, n-6).
22. The method of claim 2 wherein the composition is administered enterally.
23. The method of claim 3 wherein the composition is in a form selected from the group consisting of medicament, functional food and nutritive product.
24. The method of claim 3 wherein the composition comprises about 25% to about 70% MCT (medium chain triglycerides) by weight of total lipid and less than about 15% by weight saturated fatty acids excluding MCT.
25. The method of claim 3 wherein the composition comprises a n-6/n-3 fatty acid ratio of about 2/1 to about 7/1.

26. The method of claim 3 wherein the composition comprises at least one n-3 fatty acid selected from the group consisting of  $\alpha$ -linolenic acid, EPA, DPA and DHA.

27. The method of claim 3 wherein the composition comprises at least one n-6 fatty acid selected from the group consisting of linoleic acid (18:2, n-6),  $\gamma$ -linolenic acid (18:3, n-6), dihomo- $\gamma$ -linolenic acid (18:4, n-6) and arachidonic acid (20:4, n-6).

28. The method of claim 3 wherein the composition is administered enterally.

29. The method of claim 10 wherein the composition is in a form selected from the group consisting of medicament, functional food and nutritive product.

HS 30. The method of claim 10 wherein the composition comprises about 25% to about 70% MCT (medium chain triglycerides) by weight of total lipid and less than about 15% by weight saturated fatty acids excluding MCT.

31. The method of claim 10 wherein the composition comprises a n-6/n-3 fatty acid ratio of about 2/1 to about 7/1.

32. The method of claim 10 wherein the composition comprises at least one n-3 fatty acid selected from the group consisting of  $\alpha$ -linolenic acid, EPA, DPA and DHA.

33. The method of claim 10 wherein the composition comprises at least one n-6 fatty acid selected from the group consisting of linoleic acid (18:2, n-6),  $\gamma$ -linolenic acid (18:3, n-6), dihomo- $\gamma$ -linolenic acid (18:4, n-6) and arachidonic acid (20:4, n-6).

34. The method of claim 10 wherein the composition is administered enterally.

35. The method of claim 16 wherein the composition is in a form selected from the group consisting of medicament, functional food and nutritive product.

36. The method of claim 16 wherein the composition comprises about 25% to about 70% MCT (medium chain triglycerides) by weight of total lipid and less than about 15% by weight saturated fatty acids excluding MCT.